These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 7070886)

  • 21. A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children.
    Gross PA; Ennis FA; Gaerlan PF; Denson LJ; Denning CR; Schiffman D
    J Infect Dis; 1977 Nov; 136(5):623-32. PubMed ID: 335000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Responses of elderly subjects to monovalent A/USSR/77 (H1N1) and Trivalent A/USSR/77 (H1N1)-A/TEXAS/77 (H3N2)-B/Hong Kong/72 vaccines.
    Brandriss MW; Betts RF; Mathur U; Douglas RG
    Am Rev Respir Dis; 1981 Dec; 124(6):681-4. PubMed ID: 7316272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.
    Vesikari T; Groth N; Karvonen A; Borkowski A; Pellegrini M
    Vaccine; 2009 Oct; 27(45):6291-5. PubMed ID: 19840662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine.
    Belshe RB; Gruber WC; Mendelman PM; Mehta HB; Mahmood K; Reisinger K; Treanor J; Zangwill K; Hayden FG; Bernstein DI; Kotloff K; King J; Piedra PA; Block SL; Yan L; Wolff M
    J Infect Dis; 2000 Mar; 181(3):1133-7. PubMed ID: 10720541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.
    Nolan T; Richmond PC; Formica NT; Höschler K; Skeljo MV; Stoney T; McVernon J; Hartel G; Sawlwin DC; Bennet J; Ryan D; Basser RL; Zambon MC
    Vaccine; 2008 Nov; 26(50):6383-91. PubMed ID: 18801398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Local and systemic antibody response after vaccination with 3 different types of vaccines against influenza I. Hemagglutinationinhibiting antibodies (author's transl)].
    Kuwert EK; Werner J; Scheiermann N; Pledt T
    Zentralbl Bakteriol Orig A; 1979 Jul; 244(2-3):155-74. PubMed ID: 506543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical reactions and antibody responses to influenza vaccines. A comparison of split or subunit vaccines in children and young adults.
    Bernstein DI; Cherry JD
    Am J Dis Child; 1983 Jul; 137(7):622-6. PubMed ID: 6858973
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
    Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses.
    Engler RJ; Nelson MR; Klote MM; VanRaden MJ; Huang CY; Cox NJ; Klimov A; Keitel WA; Nichol KL; Carr WW; Treanor JJ;
    Arch Intern Med; 2008 Dec; 168(22):2405-14. PubMed ID: 19064822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines.
    Hehme N; Engelmann H; Künzel W; Neumeier E; Sänger R
    Med Microbiol Immunol; 2002 Dec; 191(3-4):203-8. PubMed ID: 12458361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice.
    Hovden AO; Cox RJ; Haaheim LR
    Scand J Immunol; 2005 Jul; 62(1):36-44. PubMed ID: 16092921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older.
    Kerzner B; Murray AV; Cheng E; Ifle R; Harvey PR; Tomlinson M; Barben JL; Rarrick K; Stek JE; Chung MO; Schödel FP; Wang WW; Xu J; Chan IS; Silber JL; Schlienger K
    J Am Geriatr Soc; 2007 Oct; 55(10):1499-507. PubMed ID: 17908055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Capacity of anti-influenza subunit vaccines to elicit the formation of heterologous antibodies].
    Profeta ML; Ferrante P
    Boll Ist Sieroter Milan; 1981; 60(4):268-77. PubMed ID: 6895694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 May; 58(19):521-4. PubMed ID: 19478718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Humoral and cellular immune responses in children given annual immunization with trivalent inactivated influenza vaccine.
    Zeman AM; Holmes TH; Stamatis S; Tu W; He XS; Bouvier N; Kemble G; Greenberg HB; Lewis DB; Arvin AM; Dekker CL
    Pediatr Infect Dis J; 2007 Feb; 26(2):107-15. PubMed ID: 17259871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly.
    Ruf BR; Colberg K; Frick M; Preusche A
    Infection; 2004 Aug; 32(4):191-8. PubMed ID: 15293073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential for single high-dose influenza immunization in unprimed children.
    Gross PA; Quinnan GV; Gaerlan PF; Denning CR; Davis A; Lazicki M; Bernius M
    Pediatrics; 1982 Dec; 70(6):982-6. PubMed ID: 7145555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and tolerability of inactivated flu vaccine in high risk and healthy children.
    Avila Aguero ML; Soriano-Fallas A; Umaña-Sauma MA; Ulloa-Gutierrez R; Arnoux S
    Medicina (B Aires); 2007; 67(4):351-9. PubMed ID: 17891930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antigenicity and reactogenicity of influenza A/USSR/77 virus vaccine in children--a multicentered evaluation of dosage and safety.
    Wright PF; Cherry JD; Foy HM; Glezen WP; Hall CB; McIntosh K; Monto AS; Parrott RH; Portnoy B; Taber LH
    Rev Infect Dis; 1983; 5(4):758-64. PubMed ID: 6353530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N; Mastrobattista E; Glansbeek H; Heldens J; van den Bosch H; Schijns V; Betbeder D; Vromans H; Jiskoot W
    Vaccine; 2008 Dec; 26(51):6555-63. PubMed ID: 18848856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.